Business Description
Krystal Biotech Inc
NAICS : 325412
SIC : 2836
ISIN : US5011471027
Total Employee Number:
295Compare
Compare
Traded in other countries / regions
KRYS.USA4KB.Germany1KRYS.ItalyK1YS34.Brazil Index Membership
Russell 2000Russell 3000 IPO Date
2017-09-20Description
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 90.37 | |||||
Equity-to-Asset | 0.91 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | 0.05 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 51.59 | |||||
Beneish M-Score | -2.32 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Book Growth Rate | 27.3 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 26.63 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 29.57 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 32.5 | |||||
9-Day RSI | 38.98 | |||||
14-Day RSI | 44.88 | |||||
3-1 Month Momentum % | 24.46 | |||||
6-1 Month Momentum % | 18.78 | |||||
12-1 Month Momentum % | 126.09 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 9.46 | |||||
Quick Ratio | 9.06 | |||||
Cash Ratio | 7.64 | |||||
Days Inventory | 544.99 | |||||
Days Sales Outstanding | 104.75 | |||||
Days Payable | 57.64 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -4.3 | |||||
Shareholder Yield % | -0.01 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 94.17 | |||||
Operating Margin % | 42.81 | |||||
Net Margin % | 53.93 | |||||
EBITDA Margin % | 44.4 | |||||
FCF Margin % | 56.88 | |||||
OCF Margin % | 59.97 | |||||
ROE % | 19.88 | |||||
ROA % | 18.2 | |||||
ROIC % | 43.4 | |||||
3-Year ROIIC % | 121.38 | |||||
ROC (Joel Greenblatt) % | 72.69 | |||||
ROCE % | 15.63 | |||||
Years of Profitability over Past 10-Year | 3 | |||||
Moat Score | 7 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 45.03 | |||||
Forward PE Ratio | 44.28 | |||||
PE Ratio without NRI | 45.03 | |||||
Price-to-Owner-Earnings | 52.94 | |||||
PS Ratio | 24.31 | |||||
PB Ratio | 7.77 | |||||
Price-to-Tangible-Book | 7.76 | |||||
Price-to-Free-Cash-Flow | 42.81 | |||||
Price-to-Operating-Cash-Flow | 40.65 | |||||
EV-to-EBIT | 51.02 | |||||
EV-to-Forward-EBIT | 41.73 | |||||
EV-to-EBITDA | 49.19 | |||||
EV-to-Forward-EBITDA | 41.73 | |||||
EV-to-Revenue | 21.84 | |||||
EV-to-Forward-Revenue | 18 | |||||
EV-to-FCF | 38.4 | |||||
Price-to-GF-Value | 1.06 | |||||
Price-to-Projected-FCF | 10.52 | |||||
Price-to-Graham-Number | 3.94 | |||||
| Price-to-Net-Current-Asset-Value | 11.01 | |||||
| Price-to-Net-Cash | 14.08 | |||||
Earnings Yield (Greenblatt) % | 1.96 | |||||
FCF Yield % | 2.39 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:KRYS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Krystal Biotech Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 417.304 | ||
| EPS (TTM) ($) | 7.48 | ||
| Beta | 0.812 | ||
| 3-Year Sharpe Ratio | 0.96 | ||
| 3-Year Sortino Ratio | 1.8 | ||
| Volatility % | 31.91 | ||
| 14-Day RSI | 44.88 | ||
| 14-Day ATR ($) | 15.833719 | ||
| 20-Day SMA ($) | 359.8435 | ||
| 12-1 Month Momentum % | 126.09 | ||
| 52-Week Range ($) | 130.5002 - 382.535 | ||
| Shares Outstanding (Mil) | 29.48 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Krystal Biotech Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Krystal Biotech Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-03 08:30 | In 104 days | ||
| Third quarter earnings results for 2026 | 2026-11-03 | In 103 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-04 08:30 | In 13 days | ||
| Second quarter earnings results for 2026 | 2026-08-04 | In 12 days | ||
| General meeting for 2026 | 2026-05-15 16:00 | 316.30 (-0.15%) | ||
| Guidance call for 2026 | 2026-05-13 11:20 | 310.31 (-0.96%) | ||
| First quarter earnings conference call for 2026 | 2026-05-04 08:30 | 266.04 (+1.11%) | ||
| First quarter earnings results for 2026 | 2026-05-04 | 266.04 (+1.11%) | ||
| TD Cowen 46th Annual Health Care Conference | 2026-03-03 15:10 | 258.81 (-3.28%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-17 08:30 | 276.45 (+1.91%) |
Show
Entries
Krystal Biotech Inc Frequently Asked Questions
What is Krystal Biotech Inc(KRYS)'s stock price today?
The current price of KRYS is $336.43. The 52 week high of KRYS is $382.54 and 52 week low is $130.50.
When is next earnings date of Krystal Biotech Inc(KRYS)?
The next earnings date of Krystal Biotech Inc(KRYS) is 2026-08-04 Est..
Does Krystal Biotech Inc(KRYS) pay dividends? If so, how much?
Krystal Biotech Inc(KRYS) does not pay dividend.
Guru Commentaries on NAS:KRYS
No articles.
Press Release
Articles on Krystal Biotech Inc
Headlines
See More- 1
Jul 20, 2026
Krystal Biotech joins the S&P MidCap 400 as TMHC and AVNS exit indexes
Seeking Alpha • 5:06pm
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers